The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Why do SGLT2 inhibitors reduce heart failure hospitalization? Adifferential volume regulation hypothesis
Open accessAbstract
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA‐REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure. We hypothesize that osmotic diuresis induced by SGLT2 inhibition, a distinctly different diuretic mechanism than that of other diuretic classes, results in greater electrolyte‐free water clearance and, ultimately, in greater fluid clearance from the interstitial fluid (IF) space than from the circulation, potentially resulting in congestion relief with minimal impact on blood volume, arterial filling and organ perfusion. We utilize a mathematical model to illustrate that electrolyte‐free water clearance results in a greater reduction in IF volume compared to blood volume, and that this difference may be mediated by peripheral sequestration of osmotically inactive sodium. By coupling the model with data on plasma and urinary sodium and water in healthy subjects who received either the SGLT2i dapagliflozin or loop diuretic bumetanide, we predict that dapagliflozin produces a 2‐fold greater reduction in IF volume compared to blood volume, while the reduction in IF volume with bumetanide is only 78% of the reduction in blood volume. Heart failure is characterized by excess fluid accumulation, in both the vascular compartment and interstitial space, yet many heart failure patients have arterial underfilling because of low cardiac output, which may be aggravated by conventional diuretic treatment. Thus, we hypothesize that, by reducing IF volume to a greater extent than blood volume, SGLT2 inhibitors might provide better control of congestion without reducing arterial filling and perfusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT-2i has a role of improving the multi-functional status of cardiovascular activities, although the diuretics seem to elicit a more powerful effect on reducing fluid retention.64,65”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [64]
In the citing paper
“In addition, a study that coupled plasma and urinary water and electrolyte data with mathematical modeling to compare effects of dapagliflozin and bumetanide on volumes of blood and interstitial fluid suggested that SGLT2 inhibitors have a preferential effect to mobilize fluid from the interstitial compartment rather than the intravascular space (38).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [38]
In the citing paper
“Mathematical analyses suggest that the excess electrolyte-free water clearance associated with osmotic diuresis may result in greater clearance of interstitial fluid compared with other forms of diuretics (14).”
From Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data (2018) · cites this paper as [14]
In the citing paper
“This suggests that the capacity to store Na ϩ peripherally is associated with an ability to clear interstitial fluid, as we have described previously (14).”
From Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data (2018) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Francis, G. S., SIEGEL, R. M., Goldsmith, S. R., OLIVARI, M. T., Levine, T. B., & Cohn, J. N. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-1-1 · Cited by 577
Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure
Weinfeld, M. S., Chertow, G. M., & Stevenson, L. W. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70113-4 · Cited by 279
Peacock, W. F., Costanzo, M. R., Marco, T. D., Lopatin, M., Wynne, J., Mills, R. M., & Emerman, C. L. (2008) · Cardiology · doi:10.1159/000164149 · Cited by 263
Body Fluid Volume Regulation in Health and Disease: A Unifying Hypothesis
Schrier, R. W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-155 · Cited by 263
Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD
Schneider, M. P., Raff, U., Kopp, C., Scheppach, J. B., Toncar, S., Wanner, C., Schlieper, G., Saritas, T., Floege, J., Schmid, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060662 · Cited by 195
Greenberg, A. (2000) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40676-7 · Cited by 154
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 496
Sudden cardiac death prevention in the era of novel heart failure medications
Koev, I., Yarkoni, M., Luria, D. M., Amir, O., & Biton, Y. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100281 · Cited by 6
Kawada, T., Yamamoto, H., Yokoi, A., Nishiura, A., Kakuuchi, M., Yokota, S., Matsushita, H., Alexander, J., & Saku, K. (2023) · The Journal of Physiological Sciences · doi:10.1186/s12576-023-00861-9 · Cited by 6
Mercier, A., Ueckert, S., Sunnåker, M., Hamrén, B., Ambery, P., Greasley, P. J., & Åstrand, M. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3362 · Cited by 5
Self-citationImpact of SGLT2 Inhibitor Therapy on Patients Undergoing Cardiac Surgery
Taghiyev, Z. T., Beier, L.-M., Leweling, C., Gunkel, S., Sadowski, K. M., Aßmus, B., & Böning, A. (2025) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/a-2616-4962 · Cited by 5
Liu, T., Fan, Z., Li, Y., Xiao, B., & Chang, H. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040382 · Cited by 5
Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management
Vahid, S. S., Jahromi, M. S., Moukarbel, G. V., & Hill, J. W. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.11.004 · Cited by 6
SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge
Buonpane, A., Ciardetti, M., Trimarchi, G., Scalone, G., Coceani, M. A., Pastormerlo, L. E., Marchi, F., Paradossi, U., Berti, S., Passino, C., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062260 · Cited by 5
Dębska-Kozłowska, A., Książczyk, M., & Lelonek, M. (2022) · Advances in Medical Sciences · doi:10.1016/j.advms.2022.01.003 · Cited by 5
Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide
Khan, M. J., Graham, F. J., Masini, G., Iaconelli, A., Friday, J. M., Lang, C. C., & Pellicori, P. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01865-y · Cited by 5
Hassan, A., Samaan, K., Asfour, A. M. S., Baghdady, Y., & Samaan, A. A. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00508-z · Cited by 5
The role of sodium glucose co-transporter inhibitors in heart failure prevention
Garla, V. V., Subauste, A. R., Butler, J., & Lien, L. F. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107811 · Cited by 5
SGLT2 inhibitors: expanding their Empire beyond diabetes
Muskiet, M. H. A., Heerspink, H. J. L., & van Raalte, D. H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30428-9 · Cited by 5
Disease-modifier Drugs in Patients with Advanced Heart Failure
Iacoviello, M., Vitale, E., Corbo, M. D., Correale, M., & Brunetti, N. D. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.05.002 · Cited by 5
Gliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura
González, V. (2021) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.36.2.8 · Cited by 6
The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
Gitto, M., Villaschi, A., Federici, M., Condorelli, G., & Stefanini, G. G. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230217143324 · Cited by 6
Ndiaye, J. F., Nekka, F., & Craig, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031002 · Cited by 5
SGLT2 Inhibitor: an Emerging Pillar in Heart Failure Therapeutics?
GEAVLETE, B. F., Popescu, R.-I., Iordache, V., Georgescu, D. E., & Geavlete, P. A. (2023) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2023.18.1.102 · Cited by 7
Anastasiou, G., Hatziagelaki, E. E., & Liberopoulos, E. N. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001011 · Cited by 6
SGLT-2 Inhibitor Use in Heart Failure
March, K. L., Lukas, J. G., Berei, T. J., Shah, S. P., & Cave, B. E. (2022) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000401 · Cited by 7
Shi, S., Li, X., Chen, Y., Li, J., & Dai, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70044 · Cited by 4
Montomoli, M., González, M., Górriz, J. L., Montesa, M. J. P., Marín, G. N., & Lecueder, M. S. (2025) · Cardiorenal Medicine · doi:10.1159/000545017 · Cited by 4
Bytyqi, V., Kannenkeril, D., Kolwelter, J., Linz, P. R., Bosch, A., Striepe, K., Karg, M. V., Nagel, A. M., Uder, M., Schiffer, M., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70078 · Cited by 4
Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes
Reutens, A. T., Lekamlage, D. H., Salim, A., Shaw, J. E., Esler, M., Cooper, M. E., & Kaye, D. M. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102304 · Cited by 4
SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?
Brusnic, O., Onișor, D. M., Boicean, A., Porr, C., Sofonea, F., Anderco, P., & Ichim, C. (2025) · Life · doi:10.3390/life15121788 · Cited by 5
Masuda, T., Kariro, K., & Morishita, Y. (2026) · Hypertension Research · doi:10.1038/s41440-025-02516-1 · Cited by 4
SGLT2-is in Acute Heart Failure
Bianco, M., Nora, C. D., Maria, R. D., Mousavi, A. H., Carigi, S., Gennaro, L. D., Manca, P., Matassini, M. V., Rizzello, V., Tinti, M. D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217799 · Cited by 4
Vieira, A. B., Cavanaugh, S. M., Ciambarella, B. T., & Machado, M. V. R. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2025.1480977 · Cited by 4
Takahashi, J., & Fukumoto, Y. (2025) · Heart and Vessels · doi:10.1007/s00380-025-02592-w · Cited by 4
Tezuka, Y., Sekine, O., Hirano, A., Hanada, Y., Ikuhisa, N., Ariga, M., Azuma, C., Yamamoto, Y., Ito‐Kobayashi, J., Washiyama, M., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00950-7 · Cited by 4
Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
Mkrtumyan, A. M., Маркова, Т. Н., & Mishchenko, N. K. (2021) · Diabetes Mellitus · doi:10.14341/dm12541 · Cited by 4
Schumacher, C. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221142686 · Cited by 4
López‐Candales, A., Sawalha, K., Drees, B. M., & Norgard, N. B. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2181537 · Cited by 4
Starr, J. A., & Pinner, N. A. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231189508 · Cited by 4
Kawada, T., Li, M., Nishiura, A., Yoshida, Y., Yokota, S., Matsushita, H., Fukumitsu, M., Uemura, K., Alexander, J., & Saku, K. (2023) · The Journal of Physiological Sciences · doi:10.1186/s12576-023-00877-1 · Cited by 4
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin
Mohebi, R., Jones, P. G., Spertus, J. A., Lingvay, I., Lanfear, D. E., GOSCH, K. L., Birmingham, M. C., Kosiborod, M., Butler, J., & Januzzi, J. L. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.01.005 · Cited by 4
Georgiou, P., Shi, W., Serhiyenia, T., Akram, A., Proute, M. C., Pradeep, R., Kerolos, M. E., & Khan, S. (2021) · Cureus · doi:10.7759/cureus.18485 · Cited by 4
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Mordi, I. R., & Lang, C. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.004 · Cited by 5
SGLT2 Inhibitors: Emerging Opportunities for the Treatment of Myocardial Infarction
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_4 · Cited by 4
Saad, M. S. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.08 · Cited by 4
Patoulias, D., Papadopoulos, C. E., Zografou, I., & Doumas, M. N. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000938 · Cited by 4
Umezawa, M., Fujii, Y., Orito, K., & YOSHIMOTO, R. (2025) · Journal of Veterinary Medical Science · doi:10.1292/jvms.25-0040 · Cited by 3
Special considerations of hyponatremia in the elderly patient
Refardt, J. C. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102040 · Cited by 4
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 3
Hernandez, V. K., Melville, B. T. P., & Siwaju, K. (2023) · Cureus · doi:10.7759/cureus.45290 · Cited by 3
Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
Abdullaev, O. A., Arutyunov, A. G., Vereshchak, D. P., Валерьевна, Т. Е., Коник, В. А., Былова, Н. А., Владимирович, П. Д., Kulagina, N. P., Nurieva, I. R., Zanina, T. V., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5602 · Cited by 3
Kawada, T., Yamamoto, H., Fukumitsu, M., Nishikawa, T., Matsushita, H., Yoshida, Y., Sato, K., Morita, H., Alexander, J., & Saku, K. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00938-z · Cited by 3
Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici
Bhandari, M., Pradhan, A. K., Vishwakarma, P., Singh, A., & Sethi, R. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i10.550 · Cited by 3
Nagy, A. C., Tóth, Á., Bak, N., Ulambayar, B., Ghanem, A. S., & Sztanek, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237093 · Cited by 3
Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
Darwish, D., Kumar, P., Urs, K., & Dave, S. (2025) · Cells · doi:10.3390/cells14120919 · Cited by 4
Nodari, S., Fioretti, F., & Barillà, F. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10203-9 · Cited by 3
Sodium–Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews
Fang, Y., Chen, L., Sun, S., & Ran, X. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11070198 · Cited by 3
Evaluation of Dapagliflozin in the Treatment of Heart Failure
Sotirakos, S. (2020) · Future Cardiology · doi:10.2217/fca-2020-0138 · Cited by 3
¿Son los inhibidores del receptor SGLT2 fármacos antidiabéticos o cardiovasculares?
Vargas-Delgado, A. P., Ibáñez, J. A. R., Santos‐Gallego, C. G., & Badimón, J. J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.08.001 · Cited by 3
Drug Repurposing Patent Applications January–March 2020
Mucke, H. A. (2020) · Assay and Drug Development Technologies · doi:10.1089/adt.2020.1015 · Cited by 3
Nephroprotective effect of novel oral sugar-reducing medicines: glyflosins
Zverev, Y. F., & Rykunova, A. Y. (2021) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2021-25-4-11-22 · Cited by 2
Small, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 2
Tiver, K. D., Chew, D. P., Tan, J. Y., Lambrakis, K., Pasquale, C. G. D., & Ganesan, A. N. (2024) · Heart Rhythm O2 · doi:10.1016/j.hroo.2024.12.004 · Cited by 2
SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives
Bertaina, M., Galluzzo, A., Carbonaro, C., Marzulli, A., Calcagnile, C., Sbarra, P., Franchin, L., Boccuzzi, G. G., & Iannaccone, M. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2503666 · Cited by 2
Future perspective on chronic kidney disease management
Qiu, X., Ding, X., Liu, H., & Li, Q. (2025) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2025.06.002 · Cited by 2
New potential treatment options for syndrome of inappropriate antidiuresis
Monnerat, S. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102055 · Cited by 2
Treatment of chronic hyponatremia and controversy about osmotic demyelination syndrome
Beck, J. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102067 · Cited by 2
Semirani-Nezhad, D., Roozbehi, K., Moghadam, A. S., Ebrahimi, E., Salehi, K., Hashempoor, A., Shamshiri, S., Azardar, T., Sabri, M., Moradi, A., et al. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200569 · Cited by 2
Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial
Andersen, C. F., Larsen, J. H., Omar, M., Nouhravesh, N., Kistorp, C., Tuxen, C., Knop, F. K., Madsen, P. L., Forman, J. L., Davidovski, F. S., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag010 · Cited by 2
Ikonomidis, I., Papageorgiou, A., Pavlidis, G., Georgiopoulos, G. A., Katogiannis, K., Maratou, E., Thymis, J., Pliouta, L., Kountouri, A., Korakas, E., et al. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00996.2025 · Cited by 3
Chiriacò, M., Tricò, D., Sacchetta, L., Nesti, L., Cimbalo, N., Santoni, L., Gallo, S., Baldi, S., Scozzaro, T., Giannoni, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03095-2 · Cited by 2
Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors
Vallon, V. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_828 · Cited by 2
Heart failure prevention with sodium‐glucose cotransporter 2 inhibitors
Khan, M. S., & Butler, J. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12932 · Cited by 2
Song, H., Kim, Y. R., Lee, S. E., Nam, H., Kim, H., Kyoung, D., & Kim, K. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2309303 · Cited by 2
Ehsan, P., Aburumman, R. N., Muthanna, S. I., Menon, S. R., Vithani, V., Sutariya, B., Montenegro, D. M., Chukwu, M., & Penumetcha, S. S. (2022) · Cureus · doi:10.7759/cureus.31777 · Cited by 2
Schoenborn, E. M., Skersick, P., THRASHER, C., & nd, R. L. P. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2839 · Cited by 2
杨, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.144980 · Cited by 2
Fawzi, H. A., Sabbar, R., Kadhim, S. A. A., Flayih, A., Mohammad, B. I., & Swadi, A. A. (2024) · Journal of Medicine and Life · doi:10.25122/jml-2023-0340 · Cited by 2
Diuretic Combination Therapy in Acute Heart Failure: An Updated Review
Villaschi, A., Pellegrino, M., Condorelli, G., & Chiarito, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128316596240625110337 · Cited by 2
Wang, X., Plantinga, A., Xiong, X., CROMER, S. J., Bonzel, C.-L., Panickan, V. A., Duan, R., Hou, J., & Cai, T. (2024) · JMIR Diabetes · doi:10.2196/58137 · Cited by 2
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.06.015 · Cited by 2
Khan, L. A., Sadia, K., Naveed, R., Khalid, R., Faisal, R., Bilal, A. R., Nawaz, A., Safdar, A., Siddique, T. S. B., Ahmad, S., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01741-2 · Cited by 2
DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
Wagdy, K., & Selwanos, P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.22 · Cited by 2
Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors
KHAKDE, S., Jawaid, H., Yasmin, F., Ali, M. B., & REHMAN, A. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03221-6 · Cited by 2
Kubica, J., Kubica, A., Grąbczewska, Z., Stróżecki, P., Adamski, P., Brymora, A., Donderski, R. Ł., Fabiszak, T., Flisiński, M., Gajda, R., et al. (2023) · Medical Research Journal · doi:10.5603/mrj.97187 · Cited by 2
Besmaya, B. M., & Laksono, S. (2023) · MPI (Media Pharmaceutica Indonesiana) · doi:10.24123/mpi.v5i1.5266 · Cited by 3
Yetkın, E., Çuğlan, B., Turhan, H., & Öztürk, S. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000200 · Cited by 2
Tratamiento actual de la falla cardiaca con fracción de expulsión reducida
Gándara-Ricardo, J. A., Muñoz-Ortiz, E., Aguilar-Molina, O. E., García-Rueda, K. A., Giraldo-Ramírez, S., Salamanca, J. F., & Sénior, J. M. (2021) · Acta Médica Colombiana · doi:10.36104/amc.2021.2108 · Cited by 2
Shen, X., & Shen, X. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14005 · Cited by 1
Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?
Nicholls, S. J., & Nerlekar, N. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.11.003 · Cited by 2
Harada, K., & Kario, K. (2021) · Hypertension Research · doi:10.1038/s41440-021-00799-8 · Cited by 2
Proposed mechanisms of systemic cardiovascular action of gliflosins
Zverev, Y. F., & Rykunova, A. Y. (2021) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf1915-22 · Cited by 1
Golubovskaia, D. P., Каретникова, В. Н., Олейник, И. Р., & Барбараш, О. Л. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-10-08 · Cited by 2
iSGLT2 y retirada o reducción de diurético de asa en insuficiencia cardiaca
Domingo, M., Ruiz-Cueto, M., Teis, A., Lupón, J., Alonso, N., & Bayés‐Genís, A. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.06.002 · Cited by 1
Aslan, O., & Demirci, E. E. (2023) · The European Research Journal · doi:10.18621/eurj.1349473 · Cited by 1
Huang, Y., Yu, X., & Li, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01230-3 · Cited by 1
Alazrag, W., Lambrakis, K., Pasquale, C. G. D., Joseph, M. X., Hecker, T., French, J. K., & Chew, D. P. (2025) · Next research. · doi:10.1016/j.nexres.2025.101033 · Cited by 1
Bhat, F. A., Aqil, M., Haque, S. E., Akhtar, M., Kamthan, M., & Najmi, A. K. (2026) · BioNanoScience · doi:10.1007/s12668-026-02654-x · Cited by 1
Mécanismes possibles des effets bénéfiques cardiovasculaires des inhibiteurs SGLT2
Vergès, B. L. (2019) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(19)30961-9 · Cited by 1
SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AS NEW STRATEGY OF CHRONIC HEART FAILURE MANAGEMENT
Herashchenko, A. S., & Fedorov, S. V. (2020) · Emergency Medical Service · doi:10.36740/emems202003109 · Cited by 1
Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?
Sanoudou, D., Mantzoros, C. S., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155309 · Cited by 1
Głuszek, J., & Kosicka, T. M. (2022) · Arterial Hypertension · doi:10.5603/ah.a2022.0010 · Cited by 2
Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?
Nechita, A. C. (2022) · Romanian Journal of Cardiology · doi:10.2478/rjc-2022-0035 · Cited by 1
Determinants of the Incidence of Hypertension in Indonesia
Nurjanah, N., Hidayani, W. R., & Sriagustini, I. (2023) · Journal of Public Health Sciences · doi:10.56741/jphs.v2i01.257 · Cited by 1
SGLT2i and loop diuretic withdrawal or downtitration in heart failure
Domingo, M., Ruiz-Cueto, M., Teis, A., Lupón, J., Alonso, N., & Bayés‐Genís, A. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.06.002 · Cited by 1
Metadata
- Authors
- Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W.
- Affiliations
- University of Georgia (US)
- AstraZeneca (United States) (US)
- AstraZeneca (Sweden) (SE)
- University of Glasgow (GB)
- Corresponding author
- Hallow, Karen M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-11-15
- Volume
- 20
- Issue
- 3
- Pages
- 479-487
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2763866789
- Cited by
- 499
- References
- 24
- Citations by year
- 2026: 36 · 2025: 50 · 2024: 46 · 2023: 75 · 2022: 65 · 2021: 89 · 2020: 76 · 2019: 44 · 2018: 15
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Keywords
- SGLT2 inhibitors, dapagliflozin, heart failure hospitalization, interstitial fluid volume, osmotic diuresis, fluid congestion, loop diuretics, bumetanide, EMPA-REG OUTCOME
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Adult, Benzhydryl Compounds, Blood Volume, Bumetanide, Diuresis, Diuretics, Drug Combinations, Drug Interactions, Female, Glucosides, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Osmolar Concentration, Sodium, Water-Electrolyte Imbalance, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
